Congenital disorders of glycosylation (CDG) are a growing group diseases that result from defects in genes involved in glycan biosynthesis pathways. One tetrasaccharide, i.e., Neu5Ac-α2, 6-Gal-β1, 4-GlcNAc-β1, 4-GlcNAc, was recently reported as the biomarker of ALG1-CDG, the disease caused by ALG1 deficiency. To develop a novel diagnostic method for ALG1-CDG, chemo-enzymatic synthesis of the tetrasaccharide biomarker linked to phytanyl phosphate and the biomarker’s immune stimulation were investigated in this study. The immunization study using liposomes bearing phytanyl-linked tetrasaccharide revealed that they stimulated a moderate immune response. The induced antibody showed strong binding specificity for the ALG1-CDG biomarker, indicating its potential in medical applications.

先天性糖基化疾病（CDG）是由与糖类生物合成途径有关的基因缺陷引起的增长中的疾病。最近报道了一种四糖，即Neu5Ac-α2、6-Gal-β1、4-GlcNAc-β1、4-GlcNAc，作为ALG1-CDG的生物标志物，该疾病是由ALG1缺乏引起的。为了开发一种新的ALG1-CDG诊断方法，本研究研究了与植烷磷酸酯连接的四糖生物标记物的化学酶法合成和生物标记物的免疫刺激作用。使用带有植烷酰基连接的四糖的脂质体进行的免疫研究表明，它们刺激了中等的免疫反应。诱导的抗体显示出对ALG1-CDG生物标志物的强结合特异性，表明其在医学应用中的潜力。